<DOC>
	<DOC>NCT00446563</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy</brief_summary>
	<brief_title>Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy, Left Ventricular</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Caucasian; male or female outpatients and age between 1880 years of age, inclusive. Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy and with a diastolic blood pressure &gt;=90 and &lt;= 105mmHg or with a combination therapy (limited to two active compounds) and with a diastolic blood pressure of &gt;=90 and &lt;= 100mmHg. Patients with Left Ventricular Hypertrophy Severe hypertension Symptomatic heart failure History of stroke, heart attack, coronary bypass surgery etc. Insulindependent diabetes mellitus or poorly controlled diabetes mellitus. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Left ventricular hypertrophy, hypertension, valsartan, amlodipine</keyword>
</DOC>